Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Biocon Limited ( (IN:BIOCON) ) is now available.
Biocon Limited announced that its subsidiary, Biocon Pharma Limited, in collaboration with Carnegie Pharmaceuticals LLC, has received tentative approval from the U.S. FDA for the ANDA for Rifaximin Tablets, 550 mg. This development marks a significant step for Biocon in expanding its portfolio in the U.S. market, potentially enhancing its competitive positioning and offering new treatment options for conditions like hepatic encephalopathy and irritable bowel syndrome with diarrhea.
More about Biocon Limited
Biocon Limited is a prominent player in the biopharmaceutical industry, primarily focusing on the development and manufacturing of generic active pharmaceutical ingredients (APIs) and biosimilars. The company is known for its innovative solutions in healthcare, catering to global markets with a strong emphasis on affordable and accessible medicines.
Average Trading Volume: 119,071
Technical Sentiment Signal: Buy
Current Market Cap: 469.9B INR
For a thorough assessment of BIOCON stock, go to TipRanks’ Stock Analysis page.